PedAM
Pediatric Disease Annotations & Medicines
| Disease | interstitial lung disease |
| Phenotype | C0149925|small cell lung cancer |
| Sentences | 9 |
| PubMedID- 26134440 | Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. |
| PubMedID- 26288223 | interstitial lung disease (ild) occurs in patients with non-small cell lung cancer receiving egfr inhibitors. |
| PubMedID- 25012241 | Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. |
| PubMedID- 19657749 | interstitial lung disease in patients with small cell lung cancer. |
| PubMedID- 23750540 | Crizotinib-induced acute interstitial lung disease in a patient with eml4-alk positive non-small cell lung cancer and chronic interstitial pneumonia. |
| PubMedID- 22233823 | Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. |
| PubMedID- 21036764 | Background: since advanced non-small cell lung cancer (nsclc) patients with the interstitial lung disease (ild) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. |
| PubMedID- 25563718 | Purpose: the prognosis of non-small cell lung cancer (nsclc) patients with interstitial lung disease (ild) is unclear. |
| PubMedID- 22114570 | Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease. |
Page: 1